Patents by Inventor Shahram Misaghi
Shahram Misaghi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240011066Abstract: Herein are reported modified mammalian cells wherein the expression of the MYC gene and one or more of the BAK, BAX, SIRT-1 and ICAM-1 genes has been reduced or eliminated as well as methods for the recombinant production of a heterologous polypeptide using a modified mammalian cell according to the current invention. Further reported are use of the reduction of the expression of the genes for increasing volumetric productivity, increasing cell volume, increasing viability and increasing the possible cultivation time without cell split.Type: ApplicationFiled: April 19, 2023Publication date: January 11, 2024Applicants: Genentech, Inc., Hoffmann-La Roche Inc.Inventors: Shahram Misaghi, Amy Shen, Inn Huam Yuk, Gavin Christian Barnard, Simon Auslaender, Niels Bauer, Benedikt Oswald
-
Publication number: 20230374497Abstract: The present disclosure relates to modified mammalian cells having reduced or eliminated expression of certain cellular proteins, CRISPR/Cas9 multiplex knockout strategies for making such cells, and methods of using such cells, e.g., in the context of cell-based therapy or as host cells in the production of a product of interest.Type: ApplicationFiled: February 28, 2023Publication date: November 23, 2023Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC.Inventors: Amy SHEN, Inn Huam Yuk, Peggy Wai No Ko, Shahram Misaghi, Simon Thomas Auslaender, Midori Greenwood-Goodwin, Michael Wilson Laird, Benedikt Alois Claudius Oswald
-
Patent number: 11802165Abstract: The present application relates to methods of producing a protein in fucosylated and afucosylated forms at a predetermined ratio.Type: GrantFiled: January 13, 2021Date of Patent: October 31, 2023Assignee: Genentech, Inc.Inventors: Shahram Misaghi, John B. Lowe, Bradley Richard Snedecor
-
Publication number: 20230279583Abstract: The presently disclosed subject matter relates to “Randomized Configuration Targeted Integration” (also referred to herein as “Randomized Chain Targeted Integration”) (RCTI) strategies for the generation and identification of host cells capable of expressing recombinant proteins, e.g., monoclonal antibodies, as well as compositions derived from the same, e.g., bispecific antibodies, and other complex format proteins, e.g., membrane protein complexes and other difficult to express molecules.Type: ApplicationFiled: April 3, 2023Publication date: September 7, 2023Applicant: GENENTECH, INC.Inventors: Shahram Misaghi, Bradley R. Snedecor
-
Patent number: 11634836Abstract: The presently disclosed subject matter relates to “Randomized Configuration Targeted Integration” (also referred to herein as “Randomized Chain Targeted Integration”) (RCTI) strategies for the generation and identification of host cells capable of expressing recombinant proteins, e.g., monoclonal antibodies, as well as compositions derived from the same, e.g., bispecific antibodies, and other complex format proteins, e.g., membrane protein complexes and other difficult to express molecules.Type: GrantFiled: December 27, 2021Date of Patent: April 25, 2023Assignee: Genentech, Inc.Inventors: Shahram Misaghi, Bradley R. Snedecor
-
Publication number: 20220162295Abstract: Herein is reported a method for producing an antibody-multimer-fusion polypeptide comprising (a) an antibody heavy chain and an antibody light chain, and (b) a first fusion polypeptide comprising in N- to C-terminal direction a first part of a non-antibody multimeric polypeptide, an antibody heavy chain CH1 domain or an antibody light chain constant domain, an antibody hinge region, an antibody heavy chain CH2 domain and an antibody heavy chain CH3 domain, and a second fusion polypeptide comprising in N- to C-terminal direction the second part of the non-antibody multimeric polypeptide and an antibody light chain constant domain if the first polypeptide comprises an antibody heavy chain CH1 domain or an antibody heavy chain CH1 domain if the first polypeptide comprises an antibody light chain constant domain, wherein (i) the antibody heavy chain of (a) and the first fusion polypeptide of (b), (ii) the antibody heavy chain of (a) and the antibody light chain of (a), and (iii) the first fusion polypeptide of (Type: ApplicationFiled: July 22, 2021Publication date: May 26, 2022Applicants: Hoffmann-La Roche Inc., Genentech, Inc.Inventors: Styliani Tournaviti, Shan-Hua Chung, Harald Duerr, Claudia Ferrara Koller, Amy Shen, Shahram Misaghi, Shuet Ming Yip
-
Publication number: 20220119985Abstract: The presently disclosed subject matter relates to “Randomized Configuration Targeted Integration” (also referred to herein as “Randomized Chain Targeted Integration”) (RCTI) strategies for the generation and identification of host cells capable of expressing recombinant proteins, e.g., monoclonal antibodies, as well as compositions derived from the same, e.g., bispecific antibodies, and other complex format proteins, e.g., membrane protein complexes and other difficult to express molecules.Type: ApplicationFiled: December 27, 2021Publication date: April 21, 2022Applicant: GENENTECH, INC.Inventors: Shahram MISAGHI, Bradley R. SNEDECOR
-
Publication number: 20220041672Abstract: The present disclosure relates to eukaryotic cell lines with a stable integrated loss-of-function or attenuation-of-function mutation in each of the Bax and Bak genes. Also provided are methods of producing such cell lines. This disclosure also relates to compositions and cell cultures comprising such cell lines, as well as methods of producing a product, such as a recombinant polypeptide or viral vector, using said cells, compositions and cell cultures.Type: ApplicationFiled: June 23, 2021Publication date: February 10, 2022Applicant: GENENTECH, INC.Inventors: Shahram MISAGHI, Danming TANG, Amy SHEN, Michael LAIRD
-
Publication number: 20210403943Abstract: The presently disclosed subject matter relates to targeted integration (TI) host cells suitable for the expression of recombinant proteins wherein those TI host cells have been subjected to supertransfection resulting in the random integration (RI) of exogenous nucleic acids encodes into their genome, as well as methods of producing and using said supertransfected TI host cells.Type: ApplicationFiled: June 23, 2021Publication date: December 30, 2021Applicant: GENENTECH, INC.Inventors: Amy SHEN, Shahram MISAGHI, Cynthia Young LAM
-
Publication number: 20210403953Abstract: The presently disclosed subject matter relates to targeted integration (TI) host cells suitable for the expression of recombinant proteins wherein those TI host cells have been subjected to supertransfection resulting in the random integration (RI) of exogenous nucleic acids encodes into their genome, as well as methods of producing and using said supertransfected TI host cells.Type: ApplicationFiled: June 18, 2021Publication date: December 30, 2021Applicant: GENENTECH, INC.Inventors: Amy SHEN, Shahram MISAGHI
-
Publication number: 20210309989Abstract: The present disclosure relates to methods, cells, and compositions for producing a product of interest, e.g., a recombinant protein. In particular, the present disclosure provides improved mammalian cells expressing the product of interest, where the cells (e.g., Chinese Hamster Ovary (CHO) cells) have reduced or eliminated activity, e.g., expression, of certain host cell proteins, e.g., enzymes including, but not limited to, certain lipases, esterases, and/or hydrolases.Type: ApplicationFiled: March 26, 2021Publication date: October 7, 2021Applicant: GENENTECH, INC.Inventors: Michael Wilson LAIRD, Shahram MISAGHI, Amy SHEN, Anthony TOMLINSON, Inn Huam YUK
-
Publication number: 20210214462Abstract: The present application relates to methods of producing a protein in fucosydated and afucosylated forms at a predetermined ratio.Type: ApplicationFiled: January 13, 2021Publication date: July 15, 2021Applicant: Genentech, Inc.Inventors: Shahram MISAGHI, John B. LOWE, Bradley Richard SNEDECOR
-
Patent number: 10975168Abstract: The present application relates to methods of producing a protein in fucosylated and afucosylated forms at a predetermined ratio.Type: GrantFiled: May 1, 2018Date of Patent: April 13, 2021Assignee: GENENTECH, INC.Inventors: Shahram Misaghi, John B. Lowe, Bradley Richard Snedecor
-
Publication number: 20210009988Abstract: The present disclosure relates to methods, cells and compositions for producing a product of interest, e.g., a recombinant protein. In particular, the present disclosure provides improved mammalian cells expressing the product of interests, where the cells (e.g., Chinese Hamster Ovary (CHO) cells) have modulated lactogenic activity. The present disclosure also relates to methods and compositions for modulating pyruvate kinase muscle (PKM) expression (e.g., PKM-1 expression) in a mammalian cell to thereby reduce or eliminate the lactogenic activity of the cell, as well compositions comprising a cell having reduced or eliminated lactogenic activity and methods of using the same.Type: ApplicationFiled: September 29, 2020Publication date: January 14, 2021Applicant: GENENTECH, INC.Inventors: Shahram Misaghi, Masaru Ken Shiratori, Bradley Richard Snedecor, Michael W. Laird
-
Publication number: 20210002669Abstract: The presently disclosed subject matter relates to targeted integration (TI) host cells suitable for the expression of recombinant proteins, as well as methods of producing and using said TI host cells.Type: ApplicationFiled: December 21, 2018Publication date: January 7, 2021Applicant: GENENTECH, INC.Inventors: Chi Kin Domingos Ng, Yongping Guo Crawford, Amy Shen, Meixia Zhou, Bradley R. Snedecor, Shahram Misaghi, Albert Eric Gao
-
Publication number: 20180251572Abstract: The present application relates to methods of producing a protein in fucosylated and afucosylated forms at a predetermined ratio.Type: ApplicationFiled: May 1, 2018Publication date: September 6, 2018Inventors: Shahram MISAGHI, John B. LOWE, Bradley Richard SNEDECOR
-
Publication number: 20120202985Abstract: Described herein are recombinant non-human cells and animals having an alteration of the S? region such that there is an elevated IgE level. Also described herein is an alteration in the IgH locus allows for enhanced class switch recombination (CSR) such that the desired heavy chain isotype is expressed at an elevated level relative to an unmodified cell.Type: ApplicationFiled: February 26, 2010Publication date: August 9, 2012Applicant: Genentech Inc.Inventors: Shahram Misaghi, Ali Zarrin